Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors
- 15 October 2008
- journal article
- Published by The Company of Biologists in Journal of Cell Science
- Vol. 121 (20) , 3487-3495
- https://doi.org/10.1242/jcs.016410
Abstract
Vascular endothelial growth factor A (VEGFA; hereafter referred to as VEGF) is a key regulator of physiological and pathological angiogenesis. Two families of VEGF isoforms are generated by alternate splice-site selection in the terminal exon. Proximal splice-site selection (PSS) in exon 8 results in pro-angiogenic VEGFxxx isoforms (xxx is the number of amino acids), whereas distal splice-site selection (DSS) results in anti-angiogenic VEGFxxxb isoforms. To investigate control of PSS and DSS, we investigated the regulation of isoform expression by extracellular growth factor administration and intracellular splicing factors. In primary epithelial cells VEGFxxxb formed the majority of VEGF isoforms (74%). IGF1, and TNFα treatment favoured PSS (increasing VEGFxxx) whereas TGFβ1 favoured DSS, increasing VEGFxxxb levels. TGFβ1 induced DSS selection was prevented by inhibition of p38 MAPK and the Clk/sty (CDC-like kinase, CLK1) splicing factor kinase family, but not ERK1/2. Clk phosphorylates SR protein splicing factors ASF/SF2, SRp40 and SRp55. To determine whether SR splicing factors alter VEGF splicing, they were overexpressed in epithelial cells, and VEGF isoform production assessed. ASF/SF2, and SRp40 both favoured PSS, whereas SRp55 upregulated VEGFxxxb (DSS) isoforms relative to VEGFxxx. SRp55 knockdown reduced expression of VEGF165b. Moreover, SRp55 bound to a 35 nucleotide region of the 3′UTR immediately downstream of the stop codon in exon 8b. These results identify regulation of splicing by growth and splice factors as a key event in determining the relative pro-versus anti-angiogenic expression of VEGF isoforms, and suggest that p38 MAPK-Clk/sty kinases are responsible for the TGFβ1-induced DSS selection, and identify SRp55 as a key regulatory splice factor.Keywords
This publication has 70 references indexed in Scilit:
- Recombinant human VEGF165b protein is an effective anti-cancer agent in miceEuropean Journal Of Cancer, 2008
- The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in miceBritish Journal of Cancer, 2008
- VEGF165b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapyBritish Journal of Cancer, 2008
- Expression of VEGFxxxb, the inhibitory isoforms of VEGF, in malignant melanomaBritish Journal of Cancer, 2007
- Cell stress modulates the function of splicing regulatory protein RBM4 in translation controlProceedings of the National Academy of Sciences, 2007
- Concerted regulation of nuclear and cytoplasmic activities of SR proteins by AKTNature Structural & Molecular Biology, 2005
- Sam68-Like Mammalian Protein 2, Identified by Digital Differential Display as Expressed by Podocytes, Is Induced in Proteinuria and Involved in Splice Site Selection of Vascular Endothelial Growth FactorJournal of the American Society of Nephrology, 2005
- Understanding alternative splicing: towards a cellular codeNature Reviews Molecular Cell Biology, 2005
- Activation of p38MAPK by TGF‐β in fetal rat hepatocytes requires radical oxygen production, but is dispensable for cell deathFEBS Letters, 2001
- Interleukin 10 and lnterleukin 13 Synergize to Inhibit Vascular Permeability Factor Release by Peripheral Blood Mononuclear Cells from Patients with Lipoid NephrosisNephron, 1997